KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

BackgroundKRAS is commonly mutated in non-small cell lung cancer (NSCLC); however, the prognostic and predictive impact of each G12 substitution has not been fully elucidated. The approval of specific G12C inhibitors has modified the idea of KRAS “undruggability”, and although the first-line standar...

Full description

Bibliographic Details
Main Authors: Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Luca Paglialunga, Marta Rita Gatta Michelet, Daniele Lavacchi, Rossana Berardi, Giulia Mentrasti, Giulio Metro, Ilaria Birocchi, Angelo Delmonte, Ilaria Priano, Camilla Eva Comin, Francesca Castiglione, Caterina Bartoli, Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
KRAS mutations
KRAS G12 isoforms
treatment responses
immune check-point inhibitors
PD-L1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.968064/full

Similar Items

Similar Items